Sahai, Vaibhav

Randomized Phase III trial of Pegvorhyaluronidase Alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma

Van Cutsem, E., Tempero, M. A., Sigal, D., Oh, D.-Y., Fazio, N., Macarulla, T., Hitre, E., Hammel, P., Hendifar, A. E., Bates, S. E., et al. (2020) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 499

Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours

Zhu, Z., Achreja, A., Meurs, N., Animasahun, O., Owen, S., Mittal, A., Parikh, P., Lo, T.-W., Franco-Barraza, J., Shi, J., et al. (2020) · Nature Metabolism

Pancreatic and Hepatic Oncology ResearchCancer, Hypoxia, and Metabolism

Cited by 204

Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., et al. (2019) · JCO Precision Oncology

Pancreatic and Hepatic Oncology ResearchAdvanced Breast Cancer Therapies

Cited by 94

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

Hu, Z. I., Bendell, J. C., Bullock, A., LoConte, N. K., Hatoum, H., Ritch, P., Hool, H., Leach, J. W., Sanchez, J., Sohal, D. P. S., et al. (2019) · Cancer Medicine

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 82

Democratizing LLMs: An Exploration of Cost-Performance Trade-offs in Self-Refined Open-Source Models

Shashidhar, S., Chinta, A., Sahai, V., Wang, Z., & Ji, H. (2023) · Findings of the Association for Computational Linguistics: EMNLP 2023

Topic ModelingNatural Language Processing Techniques

Cited by 9

76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

Park, J. O., Wai Meng, D. T., Hollebecque, A., Borad, M., Goyal, L., Schram, A., Cassier, P., Kamath, S. D., Dotan, E., Kim, R., et al. (2022) · Annals of Oncology

Cholangiocarcinoma and Gallbladder Cancer StudiesFibroblast Growth Factor Research

Cited by 7